GlassScriptPhysician profile
Gary J Silverman
NPI 1154476539
$1,002.67
in general payments reported to CMS, 2019-2025
13 companies · $515 in 2025
The $515 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $28.07 · 2022: $40.44 · 2023: $115 · 2024: $110 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $400 · Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $400.00 |
| Food and Beverage | $340.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $439.40 | 2023-2025 | Benlysta |
| Abbvie INC. | $207.86 | 2019-2025 | |
| Lilly USA, LLC | $115.40 | 2023-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $45.23 | 2025 | Acthar |
| Janssen Biotech, INC. | $37.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $37.33 | 2022-2024 | |
| Ucb, INC. | $31.35 | 2024 | Cimzia |
| Novartis Pharmaceuticals Corporation | $26.68 | 2025 | |
| Amgen INC. | $24.64 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.90 | 2024 | Cyltezo |
| Radius Health, INC. | $18.12 | 2024 | Tymlos |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.